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Abstract
IMPORTANCE Evidence regarding the presenting symptoms of cancer in adolescents and young
adults can support the development of early diagnosis interventions.
OBJECTIVE To examine common presenting symptoms in adolescents and young adults aged 12 to
24 years who subsequently received a diagnosis of cancer and potential variation in time to help-
seeking by presenting symptom.
DESIGN, SETTING, AND PARTICIPANTS This multicenter study is a cross-sectional analysis of the
BRIGHTLIGHT cohort study, which was conducted across hospitals in England. Participants included
adolescents and young adults aged 12 to 24 years with cancer. Information on 17 prespecified
presenting symptoms and the interval between symptom onset and help-seeking (the patient
interval) was collected through structured face-to-face interviews and was linked to national cancer
registry data. Data analysis was performed from January 2018 to August 2019.
EXPOSURES Self-reported presenting symptoms.
MAIN OUTCOMES AND MEASURES The main outcomes were frequencies of presenting symptoms
and associated symptom signatures by cancer group and the proportion of patients with each
presenting symptom whose patient interval was longer than 1 month.
RESULTS The study population consisted of 803 adolescents and young adults with valid symptom
information (443 male [55%]; 509 [63%] aged 19-24 years; 705 [88%] White). The number of
symptoms varied by cancer group: for example, 88 patients with leukemia (86%) presented with 2
or more symptoms, whereas only 9 patients with melanoma (31%) presented with multiple
symptoms. In total, 352 unique symptom combinations were reported, with the 10 most frequent
combinations accounting for 304 patients (38%). Lump or swelling was reported by more than
one-half the patients (419 patients [52%; 95% CI, 49%-56%]). Other common presenting symptoms
across all cancers were extreme tiredness (308 patients [38%; 95% CI, 35%-42%]), unexplained
pain (281 patients [35%; 95% CI, 32%-38%]), night sweats (192 patients [24%; 95% CI, 21%-27%]),
lymphadenopathy (191 patients [24%; 95% CI, 21%-27%]), and weight loss (190 patients [24%; 95%
CI, 21%-27%]). The relative frequencies of presenting symptoms also varied by cancer group; some
symptoms (such as lump or swelling) were highly prevalent across several cancer groups (seen in
>50% of patients with lymphomas, germ cell cancers, carcinomas, bone tumors, and soft-tissue
sarcomas). More than 1 in 4 patients (27%) reported a patient interval longer than 1 month; this
varied from 6% (1 patient) for fits and seizures to 43% (18 patients) for recurrent infections.
(continued)
Key Points
Question What are the common
presenting symptoms of cancer in
adolescents and young adults aged 12 to
24 years and how are they associated
with help-seeking?
Findings This cross-sectional analysis
of 803 adolescents and young adult
patients found a range of presenting
symptoms in diverse combinations,
which varied by cancer group; 27% of
patients waited more than 1 month to
seek help for their symptoms.
Meaning These findings suggest that
adolescents and young adults with
cancer present with a broad spectrum of
symptoms, often at substantially higher
proportions than previously reported;
thus, re-examination of symptom
prevalence in this patient group is
warranted.
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Abstract (continued)
CONCLUSIONS AND RELEVANCE Adolescents and young adults with cancer present with a broad
spectrum of symptoms, some of which are shared across cancer types. These findings point to
discordant presenting symptom prevalence estimates when information is obtained from patient
report vs health records and indicate the need for further symptom epidemiology research in this
population.
JAMA Network Open. 2020;3(9):e2015437. doi:10.1001/jamanetworkopen.2020.15437
Introduction
Cancer among adolescents and young adults is rare but remains the most common cause of
nonaccidental death in high-income countries.1 There are no effective interventions to support
asymptomatic detection through population screening for most of this group, but expediting the
diagnosis of individuals with symptoms may help improve clinical and patient-reported outcomes.2-8
Adolescents and young adults often experience prolonged intervals between onset of
symptoms and diagnosis, more so than older adults with cancer.9-12 A critical component of overall
diagnostic timeliness is the time between symptom onset and presentation, also known as the
patient interval.13 Public health education campaigns are increasingly used as part of early diagnosis
strategies to shorten this interval by promoting timely help-seeking.14-17 Indeed, improving symptom
awareness has been identified as a research priority to improve early diagnosis for adolescents and
young adults with cancer.18
Studying the presenting symptoms of adolescents and young adult cancers can help us
understand time to help-seeking and associated variation among adolescents and young adults with
symptoms who subsequently receive a diagnosis of cancer. However, there is limited evidence
regarding the presenting symptoms of adolescents and young adults with cancer. Prior
research17,19,20 is mostly based on clinician-recorded information contained in electronic health
records (EHRs). Patient-reported data could amplify our understanding of presenting symptoms as
approaches based on the examination of patient EHRs rely on complete and accurate elicitation and
recording of symptom history during clinical encounters.21 Therefore, we aimed to examine the
nature and frequency of presenting symptoms and to describe their associated time to help-seeking
in adolescents and young adults with a subsequent diagnosis of cancer, using novel self-reported
data from a large patient cohort in England.
Methods
Data and Study Population
The BRIGHTLIGHT study was approved by the London-Bloomsbury Research Ethics Committee and
the National Health Service Health Research Authority Confidentiality Advisory Group. Participants
gave written informed consent to take part in a face-to-face survey and for clinical information to be
extracted from their EHRs; dates of diagnosis were obtained from national cancer registration
(curated by Public Health England National Cancer Registration and Analysis Service). Participants
younger than 16 years gave their assent in order to participate after consent was obtained from their
parents or guardians. Those unable to complete the survey, unable to give consent, in custodial care,
or facing imminent death were not eligible to take part in the study.22 This study follows the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
We analyzed cross-sectional patient-level data from the BRIGHTLIGHT cohort.22 A total of 1114
young people aged 12 to 24 years at diagnosis with any cancer were recruited between July 1, 2012,
and April 30, 2015, from 96 nationwide English National Health Service Trust hospitals; 830
participants completed the baseline survey.
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Information on events and intervals between symptom onset and cancer diagnosis was
collected through a structured face-to-face interview conducted with an independent survey
provider (Ipsos MORI) using a device with computer-assisted personal interviewing software, which
allows the interviewer to input data into a tablet. This has the benefit of having built-in methods for
checking errors and allows routing of questions, automatically eliminating irrelevant questions on the
basis of previous answers. The survey instrument development has been described previously23; the
survey consists of 15 domains identified by young people as important in their cancer experience,
including their experience before diagnosis. The survey questions were mainly read out by the
interviewer and answered from a prespecified list, with options for including free text and dates
where applicable.
Variables of Interest
Information on symptoms experienced before the diagnosis of cancer was ascertained through
yes-or-no responses to 16 specified symptoms (patients could respond yes to >1 symptoms), with any
other symptoms recorded as free-text responses.23 Symptoms derived from the free-text
information were either recoded as 1 of the 16 specified symptoms, or otherwise collated into a 17th
symptom category labeled as other symptoms (eTable 1 in the Supplement). Patients for whom
symptom information was missing (10 patients), not specified (14 patients), or invalid (3 patients)
were excluded from analyses (eFigure in the Supplement).
The patient interval was defined as the time from symptom onset to first presentation to the
general practitioner or accident and emergency based on responses to the structured
questionnaire.12 Participants were asked, “From the time when you first noticed a symptom of cancer
how long was it before you saw the [general practitioner or accident and emergency]?” and they
were provided with 1 of the following 6 response options: less than 1 week; 1 week up to 2 weeks;
more than 2 weeks up to 4 weeks; more than 1 month up to 3 months; more than 3 months up to 6
months; or more than 6 months up to 12 months. We aggregated response categories as more than 2
weeks, more than 1 month, or more than 3 months.12
Gender, age at diagnosis, and residential postal code (matched to Local Super Output Area and
used to derive Index of Multiple Deprivation 2015 scores), were extracted from case report forms,
whereas information on ethnicity, relationship status, and employment status was elicited through
the survey via self-report.23 Information on cancer type was extracted from cancer registry data.
There were 70 patients (8%) for whom information could not be obtained from the cancer registry;
for these patients, cancer site was taken from the self-completed survey response and cross-
validated against the extracted clinical information from case report forms.
Cancers were grouped into 9 categories using the morphology-based classification of Birch
et al24 for cancers common among the adolescent and young adult population according to their
diagnoses as coded by the International Statistical Classification of Diseases and Related Health
Problems, Tenth Revision. The 9 categories were as follows: leukemia; lymphoma; central nervous
system and other intracranial and intraspinal neoplasms (central nervous system tumors); osseous
and chondromatous neoplasms, Ewing tumor, and other neoplasms of bone (bone tumors); soft
tissue sarcomas; germ cell and trophoblastic neoplasms (germ cell cancers); melanoma and skin
carcinoma; carcinomas (except of the skin); and miscellaneous specified neoplasms not elsewhere
classified and unspecified malignant neoplasms not elsewhere classified (grouped as unclassified or
unspecified).
Supplementary Analyses
We described the proportion of patients with a patient interval of more than 1 month by presenting
symptom, stratified by cancer site (eTable 3 in the Supplement). For this analysis, we used the binary
category of 1 month or less vs more than 1 month as examined previously.12
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Statistical Analysis
We calculated the frequency of presenting symptoms among the BRIGHTLIGHT cohort and
described the resulting number of symptoms and symptom signature (ie, the nature and frequency
of different symptoms) associated with each cancer group. Subsequently, we described proportions
of patients with longer patient intervals by presenting symptom using the aforementioned 3
aggregated categories: more than 2 weeks, more than 1 month, and more than 3 months. All analyses
were conducted using STATA SE statistical software version 15.1 (StataCorp). Data analysis was
performed from January 2018 to August 2019.
Results
Frequency of Presenting Symptoms
Among 803 adolescents and young adults with valid information on symptoms, 443 (55%) were
male, 509 (63%) were aged 19 to 24 years, and 705 (88%) described their ethnicity as White, as
detailed previously.12 Lump or swelling was the most common symptom (reported by 419 patients
[52%; 95% CI, 49%-56%]), followed by extreme tiredness (308 patients [38%; 95% CI, 35%-42%])
and unexplained pain (281 patients [35%; 95% CI, 32%-38%]). Night sweats (192 patients),
lymphadenopathy (191 patients), and weight loss (190 patients) each were reported by almost
one-quarter of patients before diagnosis (24%; 95% CI, 21%-27% for all). Seven of the 17 symptoms
were reported by less than 10% of the study population (Table 1).
Number of Presenting Symptoms
Overall, there was substantial patient-level variation in symptoms experienced before cancer
diagnosis, with 557 patients (69%) reporting multiple symptoms. Patients with leukemia (88
patients [86%]) and lymphoma (200 patients [77%]) were most likely to report multiple symptoms,
whereas those with melanoma were least likely to report multiple symptoms (9 patients [31%])
Table 1. Frequency of Presenting Symptoms Among the BRIGHTLIGHT
Cohort
Symptom
Patients, No. (%) [95% CI]
(N = 803)a
Lump or swelling 419 (52) [49-56]
Extreme tiredness 308 (38) [35-42]
Unexplained pain 281 (34) [32-38]
Night sweats 192 (24) [21-27]
Lymphadenopathy 191 (24) [21-27]
Weight loss 190 (24) [21-27]
Headaches 127 (16) [13-19]
Dizziness 126 (16) [13-18]
Rash or itching 94 (12) [10-14]
Limping or mobility problems 77 (10) [8-12]
Bruising or bleeding 73 (9) [7-11]
Other symptomsb 69 (9) [7-11]
Menstrual changes 56 (7) [5-9]
Recurrent infections 47 (6) [4-8]
Mole changes 40 (5) [4-7]
Loss of vision 27 (3) [2-5]
Fits or seizures 17 (2) [1-3]
a Total sum exceeds 803 (100%) because patients could report multiple
symptoms.
b Other symptoms include symptoms with less than 2% frequency (see eTable 1
in the Supplement).
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(Figure 1 and Table 2). In total, 352 unique symptom combinations were reported, with the 10 most
frequent combinations accounting for 304 patients (38%).
Cancer Site–Specific Symptom Signatures
The symptom signature of presenting symptoms varied by cancer group (Figure 2 and eTable 2 in the
Supplement). Some symptoms were highly prevalent across several cancer groups; for example,
lump or swelling was reported in more than 50% of patients with lymphomas, germ cell cancers,
carcinomas, bone tumors, and soft-tissue sarcomas, and unexplained pain was reported by at least
25% of patients in all cancer groups apart from melanoma (1 patient [3%]) and central nervous
system tumors (7 patients [23%]). In contrast, some symptoms tended to be cancer specific (present
in at least one-quarter of adolescent and young adults with those cancers); for example, limping or
mobility problems were present in 33 patients with bone tumors (42%), bruising or bleeding were
Figure 1. Number of Symptoms Reported by Adolescent and Young Adult Cancer Patients, by Cancer Type
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Symptoms are ordered by proportion of patients reporting a single symptom. CNS indicates central nervous system and other intracranial and intraspinal neoplasms; STS,
soft-tissue sarcomas.




No. (N = 745)
Patients, No. (%), by interval
>2 wk >1 mo >3 mo
Recurrent infections 42 25 (60) 18 (43) 9 (21)
Loss of vision 21 15 (71) 8 (38) 3 (14)
Mole changes 40 25 (63) 15 (38) 10 (25)
Night sweats 179 103 (58) 64 (36) 28 (16)
Weight loss 177 94 (53) 57 (32) 28 (16)
Headaches 114 68 (60) 36 (32) 14 (12)
Menstrual changes 47 30 (64) 14 (30) 4 (9)
Unexplained pain 260 124 (48) 77 (30) 33 (13)
Extreme tiredness 282 150 (53) 83 (29) 39 (14)
Lymphadenopathy 181 89 (49) 50 (28) 22 (12)
Rash or itching 87 48 (55) 24 (28) 12 (14)
Bruising or bleeding 62 31 (50) 17 (27) 3 (5)
Dizziness 117 63 (54) 32 (27) 13 (11)
Lump or swelling 391 189 (48) 103 (26) 44 (11)
Limping or mobility problems 69 34 (49) 18 (26) 7 (10)
Other symptoms 66 29 (44) 17 (26) 6 (9)
Fits or seizures 17 6 (35) 1 (6) 1 (6)
All patients 745 358 (48) 204 (27) 91 (12)
a Symptoms are ordered by proportion of patients
with an interval between symptom onset and
diagnosis (ie, patient interval) of longer than 1 month;
columns do not sum to 745 because most patients
had multiple symptoms.
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present in 40 patients with leukemia (39%), and fits or seizures (10 patients [32%]) and loss of vision
(9 patients [29%]) were present among patients with central nervous system tumors.
Extreme tiredness was 1 of the 5 most frequent symptoms experienced before diagnosis among
8 of 9 cancer groups, ranging from 10 patients with bone tumors (13%) to 74 patients (73%) with
leukemia. Night sweats was 1 of the 10 most frequent symptoms listed for all 9 cancer groups.
Presenting Symptoms and the Patient Interval
Almost one-half (385 patients [48%]) of the 745 patients with complete information on the patient
interval had a patient interval longer than 2 weeks, 204 patients (27%) had an interval longer than 1
month, and 91 patients (12%) longer than 3 months. The proportion of patients with patient intervals
Figure 2. Frequencies of the 10 Most Common Symptoms Among Adolescent and Young Adults by Cancer Group
Lymphoma (n = 260)
Lump/swelling 157 (60%)
Lymphadenopathy 144 (55%)
Extreme tiredness 125 (48%)
Night sweats 113 (43%)
Weight loss 94 (36%)




Limping/mobility problems 21 (8%)
Germ cell cancers (n = 155)
Lump/swelling 114 (74%)
Lymphadenopathy 11 (7%)
Extreme tiredness 33 (21%)
Night sweats 14 (9%)
Weight loss 16 (10%)
Unexplained pain 65 (42%)
Other symptoms 9 (6%)
Dizziness 14 (9%)
Headaches 14 (9%)
Menstrual changes 9 (6%)
Leukemia (n = 102)
Lump/swelling 13 (13%)
Lymphadenopathy 15 (15%)
Extreme tiredness 74 (73%)
Night sweats 31 (30%)
Weight loss 36 (35%)
Bruising/bleeding 40 (39%)
Unexplained pain 33 (32%)
Other symptoms 16 (16%)
Dizziness 35 (34%)
Headaches 41 (40%)
Carcinomas (n = 94)
Lump/swelling 51 (54%)
Lymphadenopathy 12 (13%)
Extreme tiredness 36 (38%)
Night sweats 13 (14%)
Bruising/bleeding 13 (14%)
Menstrual changes 14 (15%)
Weight loss 13 (14%)
Unexplained pain 38 (40%)
Dizziness 14 (15%)
Other symptoms 11 (12%)
Bone (n = 78)
Lump/swelling 50 (64%)
Headaches 3 (4%)
Other symptoms 6 (8%)
Limping/mobility problems 33 (42%)
Extreme tiredness 10 (13%)
Night sweats 8 (10%)
Weight loss 14 (18%)
Unexplained pain 47 (60%)
Lymphadenopathy 3 (4%)
Menstrual changes 4 (5%)
STS (n = 44)
Lump/swelling 29 (66%)
Lymphadenopathy 3 (7%)
Extreme tiredness 10 (23%)
Night sweats 5 (11%)
Weight loss 7 (16%)
Limping/mobility problems 3 (7%)
Unexplained pain 15 (34%)
Other symptoms 7 (16%)
Dizziness 4 (9%)
Headaches 4 (9%)
CNS (n = 31)
Headaches 22 (71%)
Other symptoms 4 (13%)
Extreme tiredness 13 (42%)
Unexplained pain 7 (23%)
Night sweats 4 (13%)
Fits/seizures 10 (32%)
Loss of vision 9 (29%)
Weight loss 7 (23%)
Dizziness 11 (35%)
Limping/mobility problems 2 (6%)
Melanoma (n = 29)
Mole changes 24 (83%)
Lymphadenopathy 2 (7%)
Recurrent infections 1 (3%)
Lump/swelling 3 (10%)
Extreme tiredness 1 (3%)
Night sweats 2 (7%)
Weight loss 1 (3%)
Rash/itching 7 (24%)
Limping/mobility problems 1 (3%)
Unexplained pain 1 (3%)
Unclassified or unspecified (n = 10)
Lymphadenopathy 1 (10%)
Menstrual changes 2 (20%)
Extreme tiredness 6 (60%)
Night sweats 2 (20%)
Weight loss 2 (20%)
Limping/mobility problems 2 (20%)




The 5 most common symptoms across the cohort are highlighted across cancer groups
by color. Germ cell cancers comprise 119 patients with testicular germ cell cancer (77%),
11 patients with ovarian germ cell cancer (7%), and 25 patients with other germ cell
cancers (16%). See eTable 2 in the Supplement for full symptom signatures.
CNS indicates central nervous system and other intracranial and intraspinal neoplasms;
STS, soft-tissue sarcomas.
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longer than 1 month varied by presenting symptom, ranging from 6% (1 patient) for fits or seizures to
43% (18 patients) for recurrent infections, with variation by cancer site (see eTable 3 in the
Supplement for proportion of patients who had a patient interval >1 month by symptom, stratified by
cancer site).
Discussion
In a nationwide cohort of adolescents and young adults with cancer, most patients reported multiple
symptoms before diagnosis. Lump or swelling was the most commonly reported presenting
symptom, followed by extreme tiredness and unexplained pain. The nature of presenting symptoms
varied by cancer group, but there were symptoms common across all cancer types. More than
one-quarter (27%) of adolescent and young adults with cancer presented more than 1 month after
symptom onset, with some observed variation between presenting symptoms.
Literature on the nature and frequency of symptoms experienced by adolescents and young
adults before cancer diagnosis is sparse; study populations often exclude those older than 16
years.20,25,26 Most existing studies6,19,27 on adolescents and young adults are based on information
captured in EHRs. In comparison, our findings based on self-reported data indicate substantially
higher frequencies of presenting symptoms among adolescent and young adults before cancer
diagnosis. This is in line with previously observed disparities between self-reported and EHR-based
symptom frequencies among adult populations.28-30
Regarding associations between symptoms and diagnostic timeliness, a previous study26 that
examined 3 categories of symptoms (pain, growing swelling or mass, or “specific symptoms”) among
primarily older children and adolescents (ie, aged 10 years) with solid tumors found no statistically
significant evidence for variation in time to help-seeking. In our study, the sample size precluded the
use of multivariable regression to examine differences in patient interval between individual
symptoms while adjusting for potential confounders.31 Nonetheless, our observed (crude) findings
are compatible with those reported by Veneroni and colleagues26; namely, the proportion of patients
with intervals longer than a month was broadly similar between different presenting symptoms.
Our findings show that adolescents and young adults with cancer present with a higher
frequency of symptoms than previously estimated. Furthermore, although some cancer types have
relatively distinct symptom signatures dominated by a single symptom (eg, mole or skin changes and
melanoma), many presenting symptoms are shared across multiple cancer types and are often vague
and nonspecific in nature, such as extreme tiredness, unexplained pain, and night sweats.
Understanding the presenting symptoms of adolescents and young adults with cancer could
inform the design of interventions to raise awareness of cancer symptoms. Although we described
variation in the timeliness of help-seeking among the 17 studied symptoms, future (larger) studies
could examine this accounting for patient characteristics and cancer group.
Our results indicate substantially higher prevalence of presenting symptoms among
adolescents and young adults with cancer compared with previous research based on structured
items (coded entries) in EHR data.19 For example, lump or mass has previously been reported as
being present in 24% of patients with lymphoma,19 whereas patient-reported data in the present
study indicate a frequency of more than 50%; similarly, fatigue has been reported as being present
in 11% of patients with leukemia19 compared with a frequency of 73% in our data. These observations
suggest that substantial underestimation of symptoms among adolescents and young adults with
cancer is likely when using information from structured fields in EHRs, because of incompletely
coded entries or incomplete reporting of symptoms to the general practitioner by adolescents and
young adults.
It is worth considering the potential implications of the underestimation of true symptom
frequency on previously reported positive predictive values (PPVs) of presenting symptoms.19 If the
degree of undercoding of symptoms is differential between cases and controls, then this would bias
the estimation of the PPV. Specifically, greater undercoding in cases more than controls would affect
JAMA Network Open | Oncology Self-reported Symptoms and Timeliness of Help-Seeking Among Young People With Cancer
JAMA Network Open. 2020;3(9):e2015437. doi:10.1001/jamanetworkopen.2020.15437 (Reprinted) September 3, 2020 7/11
Downloaded From: https://jamanetwork.com/ on 09/08/2020
the true-positive and false-negative counts, and lead to underestimation of the PPV. In comparison,
greater undercoding in controls more than cases would affect false-positive and true-negative
counts, leading to overestimation of the PPV. Further work examining the prevalence of presenting
symptoms among adolescents and young adults with and without cancer is, therefore, merited. Use
of optimized EHRs, including free-text information (eg, decision-support systems),32 or combining
both EHR-derived information and self-reported data may be informative.33,34
Strengths and Limitations
To our knowledge, this is the largest study to date to examine the self-reported symptoms of
adolescents and young adults before cancer diagnosis. Our findings are based on a large cohort of
adolescent and young adult patients with cancer, encompassing self-reported data on both
symptoms and timeliness of help-seeking. Survey participants were largely representative of incident
cancer cases, with some underrepresentation of brain tumors, melanoma, and carcinomas.22
Although the BRIGHTLIGHT cohort represents one of the largest adolescent and young adult
study populations with diagnostic pathway information, the broad spectrum of presenting
symptoms in the cohort meant that analyses adjusting for potential confounders of interest, such as
patient characteristics and cancer group, were not possible. Specifically, the number of patients with
the outcome of interest (ie, a patient interval of >1 month) relative to the number of exposures of
interest (17 symptom categories) was too small for adjusted analyses.31
Self-reported information on symptoms and intervals to help-seeking collected retrospectively
is associated with risk of recall bias, and a priori excludes patients with poor prognosis who may die
soon after their diagnosis, leading to survival bias. We observed much higher estimates of symptom
prevalence before diagnosis than those previously estimated using data from EHRs, which are prone
to underrecording of symptoms and their duration because of incomplete disclosure or elicitation
during the consultation, and/or incomplete entering of information in the patient’s EHR, particularly
if only coded entries are used for research.21,33,35
Conclusions
Adolescents and young adults with cancer present with a broad spectrum of symptoms, some of
which are common across different cancer groups. The degree of observed variation in time to help-
seeking by presenting symptom is not large enough to enable specific targeting within awareness
campaigns. Our findings indicate substantially greater frequencies of presenting symptoms among
adolescents and young adults with cancer than previously reported; re-evaluation of their prevalence
and PPV is warranted.
ARTICLE INFORMATION
Accepted for Publication: June 20, 2020.
Published: September 3, 2020. doi:10.1001/jamanetworkopen.2020.15437
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Koo MM et al.
JAMA Network Open.
Corresponding Author: Minjoung M. Koo, PhD, Epidemiology of Cancer Healthcare and Outcomes Research
Group, Department of Behavioural Science and Health, University College London, 1-19 Torrington Pl, London
WC1E 7HB, United Kingdom (monica.koo@ucl.ac.uk).
Author Affiliations: Epidemiology of Cancer and Healthcare Outcomes Research Group, Department of
Behavioural Sciences and Health, University College London, London, United Kingdom (Koo, Lyratzopoulos);
Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol,
United Kingdom (Herbert); Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United
Kingdom (Herbert); University of Exeter Medical School, St Luke’s Campus, Exeter, United Kingdom (Abel); Centre
for Nurse, Midwife, and Allied Health Professional-led Research, University College London Hospitals NHS
JAMA Network Open | Oncology Self-reported Symptoms and Timeliness of Help-Seeking Among Young People With Cancer
JAMA Network Open. 2020;3(9):e2015437. doi:10.1001/jamanetworkopen.2020.15437 (Reprinted) September 3, 2020 8/11
Downloaded From: https://jamanetwork.com/ on 09/08/2020
Foundation Trust, London, United Kingdom (Taylor); Department of Statistical Science, University College London,
London, United Kingdom (Barber); Centre for Outcomes and Experience Research in Children’s Health, Illness and
Disability, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom (Gibson);
School of Health Sciences, University of Surrey, Guildford, United Kingdom (Gibson); Cancer Division, University
College London Hospitals NHS Foundation Trust, London, United Kingdom (Whelan, Fern).
Author Contributions: Dr Koo had full access to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
Concept and design: Koo, Lyratzopoulos, Taylor, Barber, Whelan, Fern.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Koo, Lyratzopoulos, Barber, Gibson, Whelan, Fern.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Koo, Lyratzopoulos, Herbert, Abel, Barber.
Obtained funding: Lyratzopoulos, Taylor, Barber, Gibson, Whelan, Fern.
Administrative, technical, or material support: Lyratzopoulos, Herbert, Taylor, Fern.
Supervision: Lyratzopoulos, Whelan, Fern.
Conflict of Interest Disclosures: Dr Koo and Prof Lyratzopoulos reported receiving grants from Cancer Research
UK during the conduct of the study. Dr Abel reported receiving grants from Cancer Research UK during the
conduct of the study. No other disclosures were reported.
Funding/Support: This article presents independent research funded by the UK National Institute for Health
Research (NIHR) under its Programme Grants for Applied Research Programme (grant RP-PG-1209-10013). Prof
Lyratzopoulos is supported by a Cancer Research UK Advanced Clinician Scientist Fellowship Award
(C18081/A18180). Prof Lyratzopoulos is Associate Director, Dr Abel is Co-investigator, and Dr Koo is a Postdoctoral
Fellow of the multi-institutional CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385).
Dr Taylor is an NIHR Senior Nurse and Midwife Research Leader. Dr Fern is funded by Teenage Cancer Trust.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and
decision to submit the manuscript for publication.
Disclaimer: The views expressed are those of the authors and not necessarily those of the UK National Health
Service (NHS), the NIHR, the Department of Health and Social Care, Teenage Cancer Trust, or Cancer Research UK.
Additional Contributions: We thank all the young people who participated in BRIGHTLIGHT and the health care
professionals who recruited them to the study.
Additional Information: This project involves data derived from patient-level information collected by the NHS as
part of the care and support of patients with cancer, collated, maintained, and quality assured by the National
Cancer Registration and Analysis Service, which is part of Public Health England.
REFERENCES
1. Force LM, Abdollahpour I, Advani SM, et al; GBD 2017 Childhood Cancer Collaborators. The global burden of
childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol.
2019;20(9):1211-1225. doi:10.1016/S1470-2045(19)30339-0
2. Mendonca SC, Abel GA, Saunders CL, Wardle J, Lyratzopoulos G. Pre-referral general practitioner consultations
and subsequent experience of cancer care: evidence from the English Cancer Patient Experience Survey. Eur J
Cancer Care (Engl). 2016;25(3):478-490. doi:10.1111/ecc.12353
3. Sandager M, Jensen H, Lipczak H, Sperling CD, Vedsted P. Cancer patients’ experiences with urgent referrals to
cancer patient pathways. Eur J Cancer Care (Engl). 2019;28(1):e12927. doi:10.1111/ecc.12927
4. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer
associated with poorer outcomes? systematic review. Br J Cancer. 2015;112(S1)(suppl):S92-S107. doi:10.1038/
bjc.2015.48
5. Tørring ML, Falborg AZ, Jensen H, et al; ICBP Working Group. Advanced-stage cancer and time to diagnosis: an
International Cancer Benchmarking Partnership (ICBP) cross-sectional study. Eur J Cancer Care (Engl). 2019;28(5):
e13100. doi:10.1111/ecc.13100
6. Jin SL, Hahn SM, Kim HS, et al. Symptom interval and patient delay affect survival outcomes in adolescent
cancer patients. Yonsei Med J. 2016;57(3):572-579. doi:10.3349/ymj.2016.57.3.572
7. Dommett RM, Pring H, Cargill J, et al. Achieving a timely diagnosis for teenagers and young adults with cancer:
the ACE “Too Young to Get Cancer?” Study. BMC Cancer. 2019;19(1):616. doi:10.1186/s12885-019-5776-0
JAMA Network Open | Oncology Self-reported Symptoms and Timeliness of Help-Seeking Among Young People With Cancer
JAMA Network Open. 2020;3(9):e2015437. doi:10.1001/jamanetworkopen.2020.15437 (Reprinted) September 3, 2020 9/11
Downloaded From: https://jamanetwork.com/ on 09/08/2020
8. Gupta S, Harper A, Ruan Y, et al. International trends in the incidence of cancer among adolescents and young
adults. J Natl Cancer Inst. 2020;53(9):1689-1699. doi:10.1093/jnci/djaa007
9. Gibson F, Pearce S, Eden T, et al. Young people describe their prediagnosis cancer experience. Psychooncology.
2013;22(11):2585-2592. doi:10.1002/pon.3325
10. Lethaby CD, Picton S, Kinsey SE, Phillips R, van Laar M, Feltbower RG. A systematic review of time to diagnosis
in children and young adults with cancer. Arch Dis Child. 2013;98(5):349-355. doi:10.1136/archdischild-2012-
303034
11. Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. Variation in number of general practitioner
consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience
Survey in England. Lancet Oncol. 2012;13(4):353-365. doi:10.1016/S1470-2045(12)70041-4
12. Herbert A, Lyratzopoulos G, Whelan J, et al. Diagnostic timeliness in adolescents and young adults with cancer:
a cross-sectional analysis of the BRIGHTLIGHT cohort. Lancet Child Adolesc Health. 2018;2(3):180-190. doi:10.
1016/S2352-4642(18)30004-X
13. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early
cancer diagnosis. Br J Cancer. 2012;106(7):1262-1267. doi:10.1038/bjc.2012.68
14. Public Health England. Be clear on cancer: current campaigns. Published 2016. Accessed February 28, 2020.
https://www.cancerresearchuk.org/health-professional/early-diagnosis-activities/be-clear-on-cancer
15. World Health Organization. Guide to cancer: early diagnosis. Published 2017. Accessed February 28, 2020. https://
apps.who.int/iris/bitstream/10665/254500/1/9789241511940-eng.pdf?ua=1
16. Centers for Disease Control and Prevention. Get the facts about gynecological cancer: inside knowledge.
Published 2017. Accessed February 28, 2020. https://www.cdc.gov/cancer/knowledge/publications/brochures.htm
17. Coven SL, Stanek JR, Hollingsworth E, Finlay JL. Delays in diagnosis for children with newly diagnosed central
nervous system tumors. Neurooncol Pract. 2018;5(4):227-233. doi:10.1093/nop/npy002
18. Aldiss S, Fern LA, Phillips RS, et al. Research priorities for young people with cancer: a UK priority setting
partnership with the James Lind Alliance. BMJ Open. 2019;9(8):e028119. doi:10.1136/bmjopen-2018-028119
19. Dommett RM, Redaniel MT, Stevens MCG, Hamilton W, Martin RM. Features of cancer in teenagers and young
adults in primary care: a population-based nested case-control study. Br J Cancer. 2013;108(11):2329-2333. doi:10.
1038/bjc.2013.191
20. Ahrensberg JM, Hansen RP, Olesen F, Schrøder H, Vedsted P. Presenting symptoms of children with cancer:
a primary-care population-based study. Br J Gen Pract. 2012;62(600):e458-e465. doi:10.3399/bjgp12X652319
21. Koo MM, Hamilton W, Walter FM, Rubin GP, Lyratzopoulos G. Symptom signatures and diagnostic timeliness in
cancer patients: a review of current evidence. Neoplasia. 2018;20(2):165-174. doi:10.1016/j.neo.2017.11.005
22. Taylor RM, Fern LA, Barber J, et al. Description of the BRIGHTLIGHT cohort: the evaluation of teenage and
young adult cancer services in England. BMJ Open. 2019;9(4):e027797. doi:10.1136/bmjopen-2018-027797
23. Taylor RM, Fern LA, Solanki A, et al. Development and validation of the BRIGHTLIGHT Survey, a patient-
reported experience measure for young people with cancer. Health Qual Life Outcomes. 2015;13(1):107. doi:10.
1186/s12955-015-0312-7
24. Birch JM, Alston RD, Kelsey AM, Quinn MJ, Babb P, McNally RJQ. Classification and incidence of cancers in
adolescents and young adults in England 1979-1997. Br J Cancer. 2002;87(11):1267-1274. doi:10.1038/sj.bjc.
6600647
25. Wilne SH, Ferris RC, Nathwani A, Kennedy CR. The presenting features of brain tumours: a review of 200
cases. Arch Dis Child. 2006;91(6):502-506. doi:10.1136/adc.2005.090266
26. Veneroni L, Mariani L, Lo Vullo S, et al. Symptom interval in pediatric patients with solid tumors: adolescents
are at greater risk of late diagnosis. Pediatr Blood Cancer. 2013;60(4):605-610. doi:10.1002/pbc.24312
27. Roskin J, Diviney J, Nanduri V. Presentation of childhood cancers to a paediatric shared care unit. Arch Dis
Child. 2015;100(12):1131-1135. doi:10.1136/archdischild-2015-308765
28. Leiva A, Esteva M, Llobera J, et al. Time to diagnosis and stage of symptomatic colorectal cancer determined
by three different sources of information: a population based retrospective study. Cancer Epidemiol. 2017;
47:48-55. doi:10.1016/j.canep.2016.10.021
29. Lim A, Mesher D, Gentry-Maharaj A, et al. Time to diagnosis of type I or II invasive epithelial ovarian cancers:
a multicentre observational study using patient questionnaire and primary care records. BJOG. 2016;123(6):
1012-1020. doi:10.1111/1471-0528.13447
30. Smith L, Pini S, Ferrari A, et al. Pathways to diagnosis for teenagers and young adults with cancer in European
nations: a pilot study. J Adolesc Young Adult Oncol. 2018;7(5):604-611. doi:10.1089/jayao.2018.0045
JAMA Network Open | Oncology Self-reported Symptoms and Timeliness of Help-Seeking Among Young People With Cancer
JAMA Network Open. 2020;3(9):e2015437. doi:10.1001/jamanetworkopen.2020.15437 (Reprinted) September 3, 2020 10/11
Downloaded From: https://jamanetwork.com/ on 09/08/2020
31. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per
variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-1379. doi:10.1016/S0895-4356(96)
00236-3
32. Delaney BC, Kostopoulou O. Decision support for diagnosis should become routine in 21st century primary
care. Br J Gen Pract. 2017;67(664):494-495. doi:10.3399/bjgp17X693185
33. Smith SM, Whitaker KL, Cardy AH, Elliott AM, Hannaford PC, Murchie P. Validation of self-reported help-
seeking, and measurement of the patient interval, for cancer symptoms: an observational study to inform
methodological challenges in symptomatic presentation research. 2020;37(1):91-97. doi:10.1093/fampra/cmz047
34. Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors associated with diagnostic intervals for
pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol. 2016;1
(4):298-306. doi:10.1016/S2468-1253(16)30079-6
35. Verheij RA, Curcin V, Delaney BC, McGilchrist MM. Possible sources of bias in primary care electronic health
record data use and reuse. J Med Internet Res. 2018;20(5):e185. doi:10.2196/jmir.9134
SUPPLEMENT.
eTable 1. Presenting Symptoms Among the BRIGHTLIGHT Cohort
eFigure. Flow Diagram Indicating Derivation of the Study Population
eTable 2. Cancer-Specific Symptom Signatures (Frequency of Symptoms by Cancer Site)
eTable 3. Percentages of a Patient Interval >1 Month Associated With Each Symptom, Stratified by Cancer Site
JAMA Network Open | Oncology Self-reported Symptoms and Timeliness of Help-Seeking Among Young People With Cancer
JAMA Network Open. 2020;3(9):e2015437. doi:10.1001/jamanetworkopen.2020.15437 (Reprinted) September 3, 2020 11/11
Downloaded From: https://jamanetwork.com/ on 09/08/2020
